drugset / Trial / NCT01207076
AHN-12 Biodistribution in Advanced Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study is a single institution phase I study for the treatment of patients with relapsed or refractory leukemia aged 12 years and older using 90Y-AHN-12.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-07
- Completion
- 2014-07
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AHN-12 | Monoclonal antibody | 0.2 mg/kg | — |
| Subject | AHN-12 | Monoclonal antibody | 0.4 mg/kg | — |
| Subject | AHN-12 | Monoclonal antibody | 0.8 mg/kg | — |
| Subject | AHN-12 | Monoclonal antibody | 1.2 mg/kg | — |
| Subject | AHN-12 | Monoclonal antibody | 1.6 mg/kg | — |
| Subject | AHN-12 | Monoclonal antibody | 2 mg/kg | — |
| Subject | AHN-12 | Monoclonal antibody | 4 unknown | — |
| Subject | AHN-12 | Monoclonal antibody | 8 unknown | — |
| Subject | AHN-12 | Monoclonal antibody | 12 unknown | — |
| Subject | AHN-12 | Monoclonal antibody | 16 unknown | — |
| Subject | AHN-12 | Monoclonal antibody | 20 unknown | — |